NASDAQ$ANNX
Annexon Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported third quarter financial results and plans to provide updates on complement therapeutic portfolio in January 2023.
Annexon reported a net loss of $35.1 million, or $0.51 per share, for the third quarter of 2022. The company's cash and cash equivalents were $269.5 million as of September 30, 2022, which is expected to fund operations into the second half of 2025.
- Company to provide portfolio updates across autoimmune, neurodegeneration and ophthalmology therapeutic franchises in early January.
- Presentations at upcoming scientific conferences highlight company’s novel approach to treating complement-mediated diseases of the body, brain and eye.
- Company well-funded with operating runway into the second half of 2025.
- Phase 2 data support the continued advancement of ANX005 for the treatment of HD, and the company plans to engage with regulators on next steps for the program by year-end.
Headline financials
Revenue & EPS history
Annexon · Revenue · Quarterly
$400K
Forward guidance
Annexon plans to provide updates and outline anticipated milestones across its business and portfolio of complement-targeted therapies in January 2023. Initial data from the ARCHER trial are anticipated in the first half of 2023, with full data after the conclusion of the six-month off-treatment period in the second half of 2023.
Tailwinds
- With compelling clinical and biomarker data from ANX005 in both Guillain-Barré Syndrome (GBS) and Huntington’s disease (HD), the company is enthusiastic about its future as it advance a late-stage GBS trial and prepare to initiate a late-stage HD trial.
- The company is on-track to evaluate data in December from multiple signal-finding studies in autoimmune franchise, as well as safety and target engagement data with ANX1502, which is progressing well through Phase 1 dose-escalation.
- ANX007 has demonstrated target engagement and tissue penetration preclinically and in patients.
- The Phase 2 ARCHER trial of ANX007 for geographic atrophy (GA) is underway, which enrolled patients with baseline characteristics consistent with those who have benefited from other complement therapies.
- The company plans to engage with regulators on next steps for ANX005 program by year-end.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+3.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
64%
14 / 22 earnings
Positive
+23.1%
Q1 2022
Best reaction
-8.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.9% | -4.6% | -7.4% | |
| Q3 2025 | -0.7% | -9.1% | +69.1% | |
| Q1 2025 | +9.4% | +8.8% | +37.6% | |
| Q4 2024 | +3.3% | +15.5% | -23.4% | |
| Q3 2024 | -6.6% | -16.6% | -32.2% | |
| Q2 2024 | +3.8% | +11.3% | +12.8% | |
| Q1 2024 | +1.5% | -8.8% | +27.2% | |
| Q4 2023 | +17.6% | +8.0% | -30.9% | |
| Q3 2023 | +16.7% | +22.4% | +23.8% | |
| Q2 2023 | -1.2% | -2.1% | -26.6% | |
| Q1 2023 | +4.2% | +3.7% | -40.7% | |
| Q4 2022 | +3.8% | -8.0% | -15.0% | |
| Q3 2022 | -0.4% | +16.6% | +15.8% | |
| Q2 2022 | +3.1% | +17.2% | +10.2% | |
| Q1 2022 | +23.1% | +25.0% | +51.2% | |
| Q4 2021 | -5.1% | -11.0% | -43.8% | |
| Q3 2021 | +1.3% | +0.2% | -3.4% | |
| Q2 2021 | -4.6% | -13.7% | +11.6% | |
| Q1 2021 | +1.1% | +9.3% | +12.6% | |
| Q4 2020 | -8.1% | -17.4% | -29.5% | |
| Q3 2020 | +3.5% | +9.1% | +13.0% | |
| Q2 2020 | +6.6% | -1.2% | +8.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro